Kobayashi Pharmaceutical Co., Ltd.
Notice Regarding the Formulation of Medium-Term Management Plan (2026-2028)
The sales target for the fiscal year ending December 2028 is 188 billion yen (CAGR +4.3%), operating income 22 billion yen (CAGR +13.8%), and ROE 10%, aiming for 30 consecutive years of dividend increases.
Key Figures
- Net Sales Target: 188 billion yen (Fiscal year ending December 2028, CAGR +4.3%)
- Operating Income Target: 22 billion yen (Fiscal year ending December 2028, CAGR +13.8%)
- Dividend: Planning 30 consecutive years of dividend increases
AI要約
Background and Theme of the Medium-Term Management Plan
Kobayashi Pharmaceutical Co., Ltd. has formulated a new medium-term management plan covering the three years from the fiscal year ending December 2026 to the fiscal year ending December 2028. Considering past quality issues related to red yeast rice products, the company aims to balance corporate trust recovery with sustainable growth. The theme is “Achieving Sustainable Growth for the Future—Building Foundations that Connect to Tomorrow,” with five strategic pillars: rebuilding trust, corporate transformation, growth of domestic business, acceleration of global expansion, and capital efficiency management.
Overview of Performance Targets and Strategies
The numerical targets for the fiscal year ending December 2028 are net sales of 188 billion yen (CAGR +4.3%), operating income of 22 billion yen (CAGR +13.8%), EBITDA of 31.5 billion yen (CAGR +10.1%), and ROE of 10%. The dividend policy aims for 30 consecutive years of dividend increases. Market conditions include impacts from the red yeast rice incident, raw material price hikes, and intensified competition. The company plans to prioritize upfront investments and quality-related expenses while targeting profit generation from the second year onward. Resource allocation focuses on quality, capital expenditures, and human resources investment to achieve sustainable growth and enhance corporate value.
